MOB Moberg Pharma AB (publ)
Moberg Pharma AB (publ), a pharmaceutical company, develops and commercializes medical products primarily in Sweden. It offers MOB-015 for the treatment of nail fungus under the Terclara brand. The company was formerly known as Moberg Derma AB (publ) and changed its name to Moberg Pharma AB (publ) in May 2013. It has license agreement with Karo Healthcare for distribution in European market. Moberg Pharma AB (publ) was incorporated in 2006 and is based in Bromma, Sweden.…
Industry Peers
Drug Manufacturers - Specialty & GenericKey Statistics
About Moberg Pharma (STO: MOB)
›
Moberg Pharma (STO: MOB) is listed on Nasdaq Stockholm, where its shares trade in SEK. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 5 employees.
The shares were at 9.830 SEK on 19 November 2026, up 2.0% over 52 weeks. Its 52-week range is 8.140 SEK to 14.12 SEK: the price is 30.4% below the high and 20.8% above the low.
Its market capitalisation is 463.79M SEK.
Moberg Pharma reports return on equity of -4.1%, an operating margin of -96.5% and revenue up 44.2% year over year.
It holds more cash than debt, a net cash position of 203.22M SEK. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. One analyst covers the stock; their mean price target of 15.00 SEK is 52.6% above the current price.